Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity
نویسندگان
چکیده
منابع مشابه
Ofatumumab: a novel monoclonal anti-CD20 antibody
Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). Ofatumumab effectively induces complement-dependent cytotoxicity (CDC) in vitro, and recent studies demonstrated that ofatumumab also effectively mediates antibody-dependent cellular cytotoxicity (ADCC). Pha...
متن کاملproduction and characterization of new anti-human cd20 monoclonal antibody
the b-cell cd20 antigen is one of the most reliable surface targets in immunotherapy of b lymphoma. in this project, we studied the production and characterization of a new monoclonal antibody against chimeric human cd20 extra loops (hcd20 exl). the results showed that clone c12h, igg2/k isotype reacted with the antigen in elisa and immunoblot. the kd value was found to be 2×10-9m and flow cyt...
متن کاملProduction and Characterization of New Anti-Human CD20 Monoclonal Antibody.
The B-cell CD20 antigen is one of the most reliable surface targets in immunotherapy of B lymphoma. In this project, we studied the production and characterization of a new monoclonal antibody against chimeric human CD20 extra loops (hCD20 exl). The results showed that clone C12H, IgG2/k isotype reacted with the antigen in ELISA and immunoblot. The Kd value was found to be 2×10(-9)M and flow cy...
متن کاملAnti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
BACKGROUND Pemphigus is a severe autoimmune blistering disorder caused by autoantibodies to desmoglein 1 and 3. The disease course is typically severe, thus requiring multiple immunosuppressive agents. The treatment is still challenging and in some patients with recalcitrant disease, therapies fail and therapeutic options are limited. OBJECTIVES To investigate whether depletion of B lymphocyt...
متن کاملTreatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).
BACKGROUND Rituximab, a chimeric monoclonal anti-CD20 antibody, has recently been used for the treatment of refractory antibody mediated autoimmune diseases such as immune mediated thrombocytopenia and haemolytic anaemia. PATIENTS Because of its novel mechanism of action, rituximab was used to treat three patients with refractory systemic antibody mediated autoimmune disorders. The first pati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Biological Chemistry
سال: 2012
ISSN: 0021-9258
DOI: 10.1074/jbc.m112.374751